GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Dianthus Therapeutics Inc (NAS:DNTH) » Definitions » Beneish M-Score

DNTH (Dianthus Therapeutics) Beneish M-Score : 13.39 (As of Mar. 18, 2025)


View and export this data going back to 2023. Start your Free Trial

What is Dianthus Therapeutics Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Warning Sign:

Beneish M-Score 13.39 higher than -1.78, which implies that the company might have manipulated its financial results.

The historical rank and industry rank for Dianthus Therapeutics's Beneish M-Score or its related term are showing as below:

DNTH' s Beneish M-Score Range Over the Past 10 Years
Min: 13.39   Med: 13.39   Max: 13.39
Current: 13.39

During the past 4 years, the highest Beneish M-Score of Dianthus Therapeutics was 13.39. The lowest was 13.39. And the median was 13.39.


Dianthus Therapeutics Beneish M-Score Historical Data

The historical data trend for Dianthus Therapeutics's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dianthus Therapeutics Beneish M-Score Chart

Dianthus Therapeutics Annual Data
Trend Dec21 Dec22 Dec23 Dec24
Beneish M-Score
- - - 13.39

Dianthus Therapeutics Quarterly Data
Dec21 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only - - - 124.08 13.39

Competitive Comparison of Dianthus Therapeutics's Beneish M-Score

For the Biotechnology subindustry, Dianthus Therapeutics's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Dianthus Therapeutics's Beneish M-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Dianthus Therapeutics's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Dianthus Therapeutics's Beneish M-Score falls into.



Dianthus Therapeutics Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Dianthus Therapeutics for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.7652+0.528 * 1+0.404 * 37.9765+0.892 * 2.2063+0.115 * 1.6107
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.6238+4.679 * -0.016895-0.327 * 0.9606
=13.39

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec24) TTM:Last Year (Dec23) TTM:
Total Receivables was $0.81 Mil.
Revenue was 1.326 + 2.172 + 1.863 + 0.874 = $6.24 Mil.
Gross Profit was 1.326 + 2.172 + 1.863 + 0.874 = $6.24 Mil.
Total Current Assets was $280.90 Mil.
Total Assets was $374.01 Mil.
Property, Plant and Equipment(Net PPE) was $1.75 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.41 Mil.
Selling, General, & Admin. Expense(SGA) was $24.99 Mil.
Total Current Liabilities was $18.45 Mil.
Long-Term Debt & Capital Lease Obligation was $1.17 Mil.
Net Income was -28.44 + -25.174 + -17.607 + -13.748 = $-84.97 Mil.
Non Operating Income was -0.514 + 0.281 + -0.111 + -0.126 = $-0.47 Mil.
Cash Flow from Operations was -27.444 + -21.267 + -14.528 + -14.941 = $-78.18 Mil.
Total Receivables was $0.48 Mil.
Revenue was 0.457 + 0.924 + 0.969 + 0.476 = $2.83 Mil.
Gross Profit was 0.457 + 0.924 + 0.969 + 0.476 = $2.83 Mil.
Total Current Assets was $177.45 Mil.
Total Assets was $179.41 Mil.
Property, Plant and Equipment(Net PPE) was $0.80 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.36 Mil.
Selling, General, & Admin. Expense(SGA) was $18.16 Mil.
Total Current Liabilities was $9.63 Mil.
Long-Term Debt & Capital Lease Obligation was $0.17 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(0.807 / 6.235) / (0.478 / 2.826)
=0.129431 / 0.169144
=0.7652

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(2.826 / 2.826) / (6.235 / 6.235)
=1 / 1
=1

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (280.904 + 1.747) / 374.008) / (1 - (177.451 + 0.8) / 179.405)
=0.244265 / 0.006432
=37.9765

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=6.235 / 2.826
=2.2063

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(0.355 / (0.355 + 0.8)) / (0.412 / (0.412 + 1.747))
=0.307359 / 0.190829
=1.6107

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(24.994 / 6.235) / (18.159 / 2.826)
=4.008661 / 6.42569
=0.6238

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((1.171 + 18.452) / 374.008) / ((0.168 + 9.631) / 179.405)
=0.052467 / 0.054619
=0.9606

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-84.969 - -0.47 - -78.18) / 374.008
=-0.016895

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Dianthus Therapeutics has a M-score of 13.39 signals that the company is likely to be a manipulator.


Dianthus Therapeutics Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Dianthus Therapeutics's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Dianthus Therapeutics Business Description

Traded in Other Exchanges
Address
7 Times Square, 43rd Floor, New York, NY, USA, 10036
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.